Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

21. Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.

Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. BACKGROUND: Heparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising (...) heparin injection on pain, haematoma, and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin (UFH) or low molecular weight heparin (LMWH). SEARCH METHODS: For this update, the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched March 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2). The CIS also searched trials registries for details of ongoing

Cochrane2017

22. Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin Lock Solutions for Open-Ended Vascular Access Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin Lock Solutions for Open-Ended Vascular Access (...) Devices: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Published on: September 13, 2017 Project Number: RA0929-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of heparin lock solutions to maintain the patency of open-ended central vascular access devices? What are the evidence-based guidelines associated with the use of heparin lock solutions to maintain the patency of open-ended central vascular

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

23. Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines

Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines | CADTH.ca Find the information you need Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical (...) Effectiveness, Safety, and Guidelines Published on: September 7, 2017 Project Number: RA0928-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness and safety of heparin 5,000 u/0.5 mL for catheter lock or flush? What are the evidence-based guidelines associated with the use of heparin for catheter lock or flush? Key Message Two systematic reviews (both including meta-analyses) were identified regarding heparin (5,000 u/0.5 mL

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

24. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. Background The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors. Methods In this multicenter (...) , randomized, registry-based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end

NEJM2017

25. Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia

Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia 28622439 2017 06 16 2017 08 01 1538-7836 15 8 2017 Aug Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia. 1640-1645 10.1111/jth.13758 Essentials We previously published a diagnostic algorithm for heparin-induced thrombocytopenia (HIT). In this study, we (...) validated the algorithm in an independent large healthcare system. The accuracy was 98%, sensitivity 82% and specificity 99%. The algorithm has potential to improve accuracy and efficiency in the diagnosis of HIT. Background Heparin-induced thrombocytopenia (HIT) is a life-threatening drug reaction caused by antiplatelet factor 4/heparin (anti-PF4/H) antibodies. Commercial tests to detect these antibodies have suboptimal operating characteristics. We previously developed a diagnostic algorithm for HIT

EvidenceUpdates2017

26. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. BACKGROUND: People with venous thromboembolism (VTE) generally are treated for five days with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin (LMWH), followed by three months of vitamin K antagonists (VKAs). Treatment with VKAs requires regular laboratory measurements and carries risk of bleeding; some patients have contraindications (...) to such treatment. Treatment with LMWH has been proposed to minimise the risk of bleeding complications. This is the second update of a review first published in 2001. OBJECTIVES: The purpose of this review was to evaluate the efficacy and safety of long term treatment (three months) with LMWH versus long term treatment (three months) with VKAs for symptomatic VTE. SEARCH METHODS: For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched November 2016

Cochrane2017

27. Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins 29296764 2018 11 13 2473-9529 1 16 2017 Jul 11 Blood advances Blood Adv Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins. 1243-1253 10.1182/bloodadvances.2017004333 Pregnancies affected by preeclampsia (PE) or fetal growth restriction (FGR) display increases in thrombin generation and reductions in angiogenesis (...) and cell growth. There is significant interest in the potential for low molecular weight heparins (LMWHs) to reduce the recurrence of PE and FGR. However, LMWH is associated with an increased risk of bleeding. Therefore, it is of vital importance to determine the exact molecular function of heparins in pregnancy if they are used as therapy for pregnant women. We aimed to determine this using our model for PE/FGR in microvascular endothelial cells. The expression of decorin, a proteoglycan, was reduced

Blood advances2017 Full Text: Link to full Text with Trip Pro

28. Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness

Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness | CADTH.ca Find the information you need Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Pharmacological Treatments for Type II Heparin-Induced Thrombocytopenia: Clinical Effectiveness Published on: April 19, 2017 Project Number: RB1085-000 Product Line (...) : Research Type: Drugs Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness the use of fondaparinux to treat patients with type II heparin-induced thrombocytopenia? What is the clinical effectiveness the use of direct oral anticoagulants to treat patients with type II heparin-induced thrombocytopenia? Key Message One systematic review and eight non-randomized studies were identified regarding the clinical effectiveness of fondaparinux and/or direct oral

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

29. Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies

Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies 29296706 2018 11 13 2473-9529 1 11 2017 Apr 25 Blood advances Blood Adv Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies. 644-651 10.1182/bloodadvances.2017004408 Anti-protamine (PRT)/heparin antibodies are a newly described class of heparin-dependent antibodies occurring in patients exposed to PRT and heparin during cardiac surgery. To understand the biologic significance (...) of anti-PRT/heparin antibodies, we developed a murine monoclonal antibody (ADA) specific for PRT/heparin complexes and compared it to patient-derived anti-PRT/heparin antibodies, as well as comparing polyclonal and monoclonal antibodies with anti-platelet factor 4 (PF4)/heparin. Using monoclonal antibodies and polyclonal patient-derived antibodies, we show distinctive binding patterns of anti-PRT/heparin antibodies as compared with PF4/heparin antibodies. Whereas heparin-induced thrombocytopenia (HIT

Blood advances2017 Full Text: Link to full Text with Trip Pro

30. Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients

Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients | CADTH.ca CADTH Document Viewer Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism (...) in General Medical and Non Orthopedic Surgical Patients Table of Contents Search this document Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients April 2017 Key Finding: Economic Evaluation The price of low-molecular-weight heparin (LMWH) has decreased since it was marketed in the mid‑1990s in Canada, while unfractionated heparin (UFH) has recently become more costly because of changes

CADTH - Plasma Products2017

31. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. BACKGROUND: Low-molecular-weight heparins (LMWHs) and heparinoids are anticoagulants that may have more powerful antithrombotic effects than standard unfractionated heparin (UFH) but a lower risk of bleeding complications. This is an update of the original Cochrane Review of these agents, first published in 2001 and last updated in 2008. OBJECTIVES: To determine whether antithrombotic (...) : ClinicalTrials.gov, EU Clinical Trials Register, Stroke Trials Registry, ISRCTN Registry and the World Health Organization (WHO) International Clinical Trials Registry Platform. SELECTION CRITERIA: Unconfounded randomised trials comparing LMWH or heparinoids with standard UFH in people with acute ischaemic stroke, in which participants were recruited within 14 days of stroke onset. DATA COLLECTION AND ANALYSIS: Two review authors independently chose studies for inclusion, assessed risk of bias and trial quality

Cochrane2017

32. Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice

Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice 29142987 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice. 695-704 10.1016/j.ekir.2017.03.003 Extracorporeal circuit (EC) anticoagulation with heparin is a key advance in hemodialysis (HD), but anticoagulation is problematic in inpatients at risk of bleeding. We (...) prospectively evaluated a heparin-avoidance HD protocol, clotting of the EC circuit (CEC), impact on dialysis efficiency, and associated risk factors in our acute care inpatients who required HD (January 17, 2014 to May 31, 2015). HD sessions without routine EC heparin were performed using airless dialysis tubing. Patients received systemic anticoagulation therapy and/or antiplatelets for non-HD indications. We observed patients for indications of CEC (interrupted HD session, circuit loss, or inability

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

33. Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice

Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: A service evaluation following a change in practice 29118829 2018 11 13 1751-1437 18 3 2017 Aug Journal of the Intensive Care Society J Intensive Care Soc Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients (...) : A service evaluation following a change in practice. 184-192 10.1177/1751143717695835 Following the implementation of citrate anticoagulation for continuous renal replacement therapy, we evaluate its first year of use and compare it to the previously used heparin, to assess whether our patients benefit from the recently reported advantages of citrate. We retrospectively analysed 2 years of data to compare the safety and efficacy of citrate versus heparin. The results have shown that 43 patients received

Journal of the Intensive Care Society2017 Full Text: Link to full Text with Trip Pro

34. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. 28273285 2017 03 08 2017 03 08 2380-6591 2017 Mar 08 JAMA cardiology JAMA Cardiol One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction (...) : A Secondary Analysis of the EUROMAX Randomized Clinical Trial. 10.1001/jamacardio.2016.5975 Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available regarding long-term mortality in the context of contemporary practice with frequent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

35. Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronaryintervention (PCI)

Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronaryintervention (PCI) Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness of bivalirudin versus heparin monotherapy for percutaneous coronary intervention (PCI) Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Anticoagulation is recommended for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Two commonly employed options include heparin and bivalirudin. Heparin is an indirect thrombin inhibitor; it binds and activates

Health Technology Assessment (HTA) Database.2017

37. BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein

BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis

Health Canada - Drug and Health Product Register2017

38. Heparin flush for central and peripheral venous access devices

Heparin flush for central and peripheral venous access devices Heparin flush for central and peripheral venous access devices Heparin flush for central and peripheral venous access devices Mitchell MD, Wilck MB, Zborowski K, Mull, N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Wilck MB, Zborowski K, Mull, N. Heparin flush (...) for central and peripheral venous access devices. Philadelphia: Center for Evidence-based Practice (CEP). 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Catheterization, Central Venous; Heparin; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA

Health Technology Assessment (HTA) Database.2017

39. Should we avoid heparin to eliminate HIT?

Should we avoid heparin to eliminate HIT? 29296689 2018 01 03 2473-9529 1 1 2016 Nov 29 Blood advances Blood Adv Should we avoid heparin to eliminate HIT? 4 10.1182/bloodadvances.2016000083 Arepally Gowthami Morey GM Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC. eng Journal Article 2016 11 22 United States Blood Adv 101698425 2473-9529 Conflict-of-interest disclosure: G.M.A. has received consultancy fees from Momenta and Apotex Pharmaceuticals (...) , makers of generic low-molecular-weight heparins. 2018 1 4 6 0 2016 11 22 0 0 2016 11 22 0 1 epublish 29296689 10.1182/bloodadvances.2016000083 000083 PMC5744050

Blood advances2016 Full Text: Link to full Text with Trip Pro

40. Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia 29296696 2018 11 13 2473-9529 1 1 2016 Nov 29 Blood advances Blood Adv Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. 62-74 10.1182/bloodadvances.2016000877 Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder initiated by antibodies to complexes between platelet factor 4 (...) (PF4) and heparin. The risk of recurrent thromboembolism persists after heparin is cleared and platelet activation leading to release of PF4 has dissipated. We asked whether antigenic complexes between polyphosphates and PF4 released from activated platelets might intensify or sustain the prothrombotic phenotype of HIT. PF4 forms stable, ultralarge complexes with polyphosphates of various sizes, including those released from platelets, which are recognized by the HIT-like monoclonal KKO

Blood advances2016 Full Text: Link to full Text with Trip Pro